MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer
Bing Li(Wuhan University), Gerald Schmit-Bindert(Heidelberg University), Caicun Zhou(Tongji University), Fei Ke(Chinese Academy of Sciences), Yayi He(Helix (United States)), Xuefei Li(Harbin Medical University), Yongsheng Wang(Nanjing Drum Tower Hospital), Mo Chen(Tongji University), Songwen Zhou(Tongji University), Peng Kuang(First Affiliated Hospital of University of South China), Lihong Fan(Wuhan University of Technology), Guanghui Gao(Tongji University), David Garfield(Shanghai Cancer Institute), Shengxiang Ren(Tongji University), Xiaoxia Chen(Shanghai Pulmonary Hospital), Chunxia Su(Tongji University)
Cited by 178
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|504